ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK And Angiochem In Rare-Diseases Pact

by Lisa M. Jarvis
March 5, 2012 | APPEARED IN VOLUME 90, ISSUE 10

To bolster its rare-diseases program, Glaxo­SmithKline is teaming up with Montreal-based Angiochem to develop treatments for lysosomal storage diseases. Angiochem gets an up-front payment of as much as $31.5 million plus research funding it will use to develop enzyme replacement therapies (ERTs) that can cross the blood-brain barrier. Current ERTs are unable to address the neurological symptoms caused by lysosomal storage diseases. Angiochem’s engineered-peptide technology overcomes those limitations by binding to the LRP1 receptor, which provides a gateway into the brain.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment